Lexapro and Gastrointestinal inflammation - a phase IV clinical study of FDA data

Summary:

Gastrointestinal inflammation is reported as a side effect among people who take Lexapro (escitalopram oxalate), especially for people who are female, 50-59 old, also take Cipro, and have Immunodeficiency common variable.

The phase IV clinical study analyzes which people have Gastrointestinal inflammation when taking Lexapro. It is created by eHealthMe based on reports of 82,231 people who have side effects when taking Lexapro from the FDA, and is updated regularly.

What is Lexapro?

Lexapro has active ingredients of escitalopram oxalate. It is often used in depression. eHealthMe is studying from 91,465 Lexapro users. Check the latest studies of Lexapro.

What is Gastrointestinal inflammation?

Gastrointestinal inflammation (inflammation of stomach and intestine) is found to be associated with 541 drugs and 548 conditions by eHealthMe. Check the latest studies of Gastrointestinal inflammation.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

82,231 people reported to have side effects when taking Lexapro.
Among them, 70 people (0.09%) have Gastrointestinal inflammation.

Could Lexapro cause Gastrointestinal inflammation?

Among these 70 people:

What is the gender of people who have Gastrointestinal inflammation when taking Lexapro? *

female: 90.91 %
male: 9.09 %

What is the age of people who have Gastrointestinal inflammation when taking Lexapro? *

What are other drugs people take besides Lexapro? *

What are other side effects people have besides Gastrointestinal inflammation? *

Pain: 41 people, 58.57%
Diarrhea: 40 people, 57.14%
Urinary Tract Infection: 37 people, 52.86%
Nausea (feeling of having an urge to vomit): 37 people, 52.86%
Fever: 36 people, 51.43%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 33 people, 47.14%
Dizziness: 32 people, 45.71%
Abdominal Pain: 32 people, 45.71%
Pain In Extremity: 31 people, 44.29%
Pain In Jaw: 31 people, 44.29%

What are the existing conditions these people have? *

Immunodeficiency Common Variable: 9 people, 12.86%
Breast Cancer: 8 people, 11.43%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 6 people, 8.57%
Metastases To Bone (cancer spreads to bone): 4 people, 5.71%
Multiple Myeloma (cancer of the plasma cells): 4 people, 5.71%
Osteoporosis (bones weak and more likely to break): 4 people, 5.71%
Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 3 people, 4.29%
Pulmonary Hypertension (increase in blood pressure in the lung artery): 2 people, 2.86%
Primary Myelofibrosis (primary disorder of the bone marrow): 2 people, 2.86%
Fear: 2 people, 2.86%

* Approximation only. Some reports may have incomplete information.

Do you take Lexapro and have Gastrointestinal inflammation?

- Check whether Gastrointestinal inflammation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lexapro:

Lexapro (91,465 reports)

Browse all side effects of Lexapro:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Gastrointestinal inflammation:

Gastrointestinal inflammation (541 drugs)

Browse all the conditions that are associated with Gastrointestinal inflammation:

Gastrointestinal inflammation (548 conditions)

Related publications that referenced our studies

Schwerd T, Pandey S, Yang HT, Bagola K, Jameson E, Jung J, Lachmann RH, Shah N, Patel SY, Booth C, Runz H, "Impaired antibacterial autophagy links granulomatous intestinal inflammation in Niemann–Pick disease type C1 and XIAP deficiency with NOD2 variants in Crohn9s disease", Gut, 2016 Mar .
O’Brien FE, O’Connor RM, Clarke G, Donovan MD, Dinan TG, Griffin BT, Cryan JF, "The P-glycoprotein inhibitor cyclosporin A differentially influences behavioural and neurochemical responses to the antidepressant escitalopram", Behavioural brain research, 2014 Mar .
Schwerd T, Pandey S, Yang HT, Bagola K, Jameson E, Jung J, Lachmann RH, Shah N, Patel SY, Booth C, Runz H, "Impaired antibacterial autophagy links granulomatous intestinal inflammation in Niemann–Pick disease type C1 and XIAP deficiency with NOD2 variants in Crohn9s disease", Gut, 2016 Mar .
O’Brien FE, O’Connor RM, Clarke G, Donovan MD, Dinan TG, Griffin BT, Cryan JF, "The P-glycoprotein inhibitor cyclosporin A differentially influences behavioural and neurochemical responses to the antidepressant escitalopram", Behavioural brain research, 2014 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on escitalopram oxalate (the active ingredients of Lexapro) and Lexapro (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.